2 blue-chip ASX 200 stock analysts urge investors to buy

Image source: Getty Images

If you’re looking to bolster your portfolio with blue chip stocks, you might want to check out the two below.

Here’s why these Blue Chip ASX 200 stocks are highly rated right now:

The first blue-chip ASX 200 stock that could be in the buy zone is CSL. It’s the biotherapy giant behind CSL Behring, which has developed a range of life-saving and lucrative plasma therapies. In addition, the company has a growing Seqirus vaccines business and is in the process of acquiring Vifor Pharma, which focuses on iron deficiency, nephrology and cardio-renal therapies.

The Morgans team is positive about the business, especially given the resumption of plasma collections. He recently put an added rating and a price target of $327.60 on his shares. Morgans commented:

“Promisingly, plasma collections continue to improve, although they remain slightly below pre-pandemic levels, and although industry-wide issues remain (e.g., Omicron; personnel; rising costs), the worst seems behind us.”

“While short-term challenges remain, the ongoing recovery in plasma collections, coupled with management confidence, paints a favorable earnings picture.”

Goodman is another blue chip ASX 200 stock to consider. It is an integrated real estate company with operations across Australia, New Zealand, Asia, Europe, UK, North America and Brazil.

The company notes that its global real estate expertise, integrated customer service + development + management offering, and significant investment management platform enable it to create innovative real estate solutions that meet the individual needs of its customers, such as Amazon , while seeking to provide long-term solutions. returns for investors.

Citi is very positive on Goodman and currently has a buy rating and price target of $29.50 on its stock. Its analysts believe Goodman could outperform its revised guidance in fiscal 2022. He commented:

“GMG’s 1H22 EPS of 41.9c was 12% higher than the Visible Alpha consensus (37.3c) and 6% higher than Citi (39.5c). The FY22 EPS guidance was updated for the second time in 6 months to 20% growth to EPS of 78.7c, +1.5% ahead of the incoming consensus of 77.5c FY22 DPS guidance was retained at 30c.

“We continue to view guidance as conservative, with our EPS estimates growing 5% in FY22 and c. 6% thereafter. We now forecast c. 23% EPS growth in FY22 and ~19% CAGR EPS from FY21-FY24 Our TP increases 5% on higher asset values ​​and higher revenues GMG remains OUR top choice in the sector.

Comments are closed.